Emanuele Marra – Director of Infectious Disease Area – and Giuseppe Roscilli – Director of Antibody Development Area – take stock of the development of our vaccine and its potential to fight the new emerging variants for coronavirus.
Luigi Aurisicchio – CEO of Takis – mentioned our collaboration with a company based in Anagni to produce our vaccine in bioreactors.
As we complete all these steps and move forward with the clinical trial, we hope COVID-eVax will be on the market by 2022.